Bristol Myers Squibb's Revlimid finally faces competition in the U.S. with Teva's generic launch

Sales of Bristol Myers Squibb’s Revlimid crescendoed at $12.8 billion in 2021, the final year of exclusivity for the multiple myeloma treatment. But now, BMS can no longer hold off generic competition.